Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Conference Correspondent
Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1–positive NSCLC
ASCO 2016 – Lung Cancer
,
ASCO
Conference Correspondent
— July 1, 2016
Read Article
Response to tyrosine kinase inhibitors in advanced non–small-cell lung cancer with concomitant c-MET overexpression and EGFR mutation
ASCO 2016 – Lung Cancer
,
ASCO
Conference Correspondent
— July 1, 2016
Read Article
Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer
ASCO 2016 – Lung Cancer
,
ASCO
Conference Correspondent
— July 1, 2016
Read Article
R-CHOP ± Bortezomib in Patients with Untreated Non-GCB DLBCL: Results from the Phase 2 PYRAMID Trial
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
— January 14, 2016
Read Article
Bortezomib/Melphalan/Prednisolone Induction Therapy Followed by Lenalidomide/Dexamethasone Consolidation and Lenalidomide Maintenance in Transplant-Ineligible Patients with Newly Diagnosed MM
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
— January 14, 2016
Read Article
The Relevance of Minimal Residual Disease Monitoring in Elderly Multiple Myeloma Patients
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
— January 14, 2016
Read Article
Patient Preferences on Treatment Attributes in MM
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
— January 14, 2016
Read Article
Management of Infusion-Related Reactions Associated with Daratumumab Monotherapy in RRMM
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
— January 14, 2016
Read Article
Final OS Analysis of Panorama 1 Trial of Panobinostat/Bortezomib/Dexamethasone in RRMM
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
— January 14, 2016
Read Article
Afatinib vs Erlotinib as Second-line Therapy of Patients with Advanced Squamous Cell Carcinoma (SCC) of the Lung: Analysis from the LUX-Lung 8 Trial
Conference Correspondent
— December 4, 2015
Read Article
Page 23 of 44
20
21
22
23
24
25
26
Top Trending Articles
1.
Immunotherapy Helps Navy Veteran Beat Stage 4 Lung Cancer
2.
HOPA Highlights: What's New in 2025?
3.
Peer Navigation Intervention Aims to Boost Childhood Cancer Clinical Trial Participation
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma